Stockreport

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

INmune Bio Inc. - Common stock  (INMB) 
PDF Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused o [Read more]